S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity and Diabetes before and after Roux-en-Y Gastric Bypass Surgery
Open Access
- 23 August 2017
- journal article
- research article
- Published by S. Karger AG in Obesity Facts
- Vol. 10 (4) , 386-395
Abstract
Background: In obesity, which is a major contributor to insulin resistance and diabetes, the circulating level of S100A8/A9 (calprotectin) is elevated and declines after Roux-en-Y gastric bypass surgery (RYGB). However, studies on S100A8/A9 and the pathophysiological mechanisms in insulin resistance and diabetes are few and contradictory. Methods: We studied 48 subjects who underwent RYGB, comprising a non-diabetic control group and two diabetic groups in whom diabetes either regressed or persisted, 6-12 months post-surgically. S100A8/A9, interleukin 6 (IL-6) as well as other inflammatory and diabetes-related markers were measured pre- and post-surgically. Results: Significant and similar decreases of BMI were found in all groups. S100A8/A9 and IL-6 decreased significantly in the group with diabetes remission and in the control group, but not in the group with persistent diabetes. The relative changes in S100A8/A9 and IL-6 correlated significantly (r = 0.905, p = 0.005) only in the group with persistent diabetes. In contrast, leukocyte count and C-reactive protein correlated significantly to S100A8/A9 only in the control group. Conclusion: Our study is suggestive of S100A8/A9 and IL-6 being related to a persistent diabetes status post-surgically and of different pathophysiological mechanisms being involved in the post-surgical changes in the three groups, despite similar decreases in BMI.Keywords
This publication has 25 references indexed in Scilit:
- Effect of different bariatric surgery type on the leukocyte formulaSurgery for Obesity and Related Diseases, 2016
- Roux-en-Y Gastric Bypass Decreases Pro-inflammatory and Thrombotic Biomarkers in Individuals with Extreme ObesityObesity Surgery, 2014
- Hyperglycemia Promotes Myelopoiesis and Impairs the Resolution of AtherosclerosisCell Metabolism, 2013
- Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetesEuropean Journal of Endocrinology, 2012
- Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesityDiabetes Research and Clinical Practice, 2012
- Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgerySurgery for Obesity and Related Diseases, 2011
- Increased Levels of Calprotectin in Obesity Are Related to Macrophage Content: Impact on Inflammation and Effect of Weight LossMolecular Medicine, 2011
- Neutrophil Activation in Morbid Obesity, Chronic Activation of Acute InflammationObesity, 2009
- Serum C-Reactive Protein and White Blood Cell Count in Morbidly Obese Surgical PatientsObesity Surgery, 2008
- Use and Abuse of HOMA ModelingDiabetes Care, 2004